This provider's $55.0M in total Medicare payments ranks in the 98th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 63% from 2014 to 2023.
67% of their billing comes from a single procedure code (G0483 — Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms).
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 189% in 2017
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $25.44 | $23.61 | 1.08x | $1.83 | $4.0M | 168.8K | 11 |
| 2015 | $74.49 | $35.63 | 2.09x | $38.86 | $5.5M | 153.5K | 17 |
| 2016 | $424.57 | $127.96 | 3.32x | $296.61 | $1.9M | 14.7K | 30 |
| 2017 | $581.47 | $189.27 | 3.07x | $392.20 | $5.4M | 28.7K | 24 |
| 2018 | $446.31 | $189.77 | 2.35x | $256.54 | $6.0M | 31.7K | 17 |
| 2019 | $266.76 | $172.02 | 1.55x | $94.74 | $6.2M | 36.1K | 21 |
| 2020 | $259.70 | $168.86 | 1.54x | $90.84 | $5.5M | 32.7K | 24 |
| 2021 | $254.86 | $166.10 | 1.53x | $88.76 | $6.8M | 40.9K | 36 |
| 2022 | $233.92 | $148.89 | 1.57x | $85.03 | $7.2M | 48.5K | 40 |
| 2023 | $236.78 | $150.19 | 1.58x | $86.59 | $6.5M | 43.2K | 29 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 146.3K | $35.5M | $242.95 | 1.96x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 70.9K | $4.6M | $64.52 | 1.78x |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 16.1K | $3.1M | $193.22 | 1.67x |
| 84999 | Chemistry procedures | 11.3K | $2.3M | $201.21 | 3.23x |
| 82542 | Chemical analysis using chromatography technique | 67.1K | $1.6M | $24.11 | 1.08x |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 4.8K | $731.2K | $152.39 | 1.67x |
| 83925 | Opiates (drug) measurement | 25.1K | $653.0K | $26.01 | 1.08x |
| G6056 | Opiate(s), drug and metabolites, each procedure | 24.3K | $621.9K | $25.64 | 1.14x |
| 82491 | Chemical analysis | 24.7K | $596.4K | $24.14 | 1.08x |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 7.6K | $580.4K | $76.45 | 1.96x |
| 80154 | Benzodiazepines level | 12.5K | $310.2K | $24.72 | 1.09x |
| G6031 | Benzodiazepines | 12.3K | $302.6K | $24.67 | 1.24x |
| G0479 | Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when | 3.6K | $281.9K | $77.62 | 1.92x |
| 83840 | Methadone level | 12.6K | $274.2K | $21.83 | 1.05x |
| G6053 | Methadone | 12.5K | $273.0K | $21.77 | 1.37x |
| 82101 | Urine alkaloids level | 6.3K | $252.1K | $40.12 | 1.07x |
| 83992 | PCP drug level | 12.6K | $247.6K | $19.60 | 1.33x |
| G6041 | Alkaloids, urine, quantitative | 6.1K | $242.7K | $40.03 | 1.25x |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 2.0K | $228.2K | $112.75 | 1.53x |
| 82649 | Dihydromorphinone (drug) level | 6.3K | $215.9K | $34.37 | 1.08x |
This provider submits charges 1.87 times higher than what Medicare actually pays.
A markup ratio of 1.87x means for every $100 Medicare pays, this provider initially charges $187. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in NC for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Laboratory Corporation Of America Holdings | Burlington, NC | $2.2B | ⚠️ Flagged |
| Pathgroup Labs, Llc | Greensboro, NC | $203.7M | ⚠️ Flagged |
| Mako Medical Laboratories, Llc | Raleigh, NC | $107.0M | ✓ Clear |
| Quest Diagnostics Clinical Laboratories Inc | Greensboro, NC | $69.3M | ⚠️ Flagged |
| Laboratory Corporation Of America Holdings | Research Triangle Park, NC | $65.4M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data